Advertisement
Advertisement
U.S. markets close in 3 hours 58 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tempest Therapeutics, Inc. (TPST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
13.56-0.34 (-2.45%)
As of 11:56AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close13.90
Open13.72
Bid13.55 x 900
Ask14.01 x 1000
Day's Range13.51 - 14.10
52 Week Range10.39 - 41.55
Volume7,811
Avg. Volume117,633
Market Cap90.896M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-20.04
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TPST

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Tempest Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 10/20/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of a presentation on TPST-1495, a selective antagonist of both EP2 and EP4 prostaglandin receptors, at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place November 10-14, 2021 at the Walter

  • GlobeNewswire

    Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche

    Trial to Evaluate TPST-1120/atezolizumab/bevacizumab triplet compared to atezolizumab/bevacizumab aloneSOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the first patient has been dosed in the global randomized Phase 1b/2 clinical study evaluating TPST-1120, Tempest’s small molecule

  • GlobeNewswire

    Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target

    • Russell Vance, PhD joins Tempest Advisory Board SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that it has entered into an exclusive license with the University of California at Berkeley for intellectual property covering a drug target that was discovered in the laboratory of R

Advertisement
Advertisement